Aleksander Skotnicki

Aleksander Skotnicki 's AcademicInfluence.com Rankings

Philosophy

#11819

World Rank

#16336

Historical Rank

Logic

#8629

World Rank

#10822

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Aleksander Skotnicki 's Degrees

Doctorate Medicine Medical University of Warsaw
PhD Hematology Medical University of Warsaw

Why Is Aleksander Skotnicki Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Aleksander Bartłomiej Skotnicki is a Polish hematologist and transplantologist, specialist in internal medicine, professor of medical sciences, Head of the Hematology Clinic of the Jagiellonian University Medical College between 1993 and 2018, academic lecturer, social activist, member of the Polish Academy of Learning.

(See a Problem?)

Aleksander Skotnicki 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. (2007) (607)
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. (2007) (296)
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. (2000) (239)
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. (2007) (226)
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. (2012) (211)
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. (2009) (153)
Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study (2008) (137)
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). (2006) (133)
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group (2007) (121)
Parkinson's syndrome preceding clinical manifestation of Gaucher's disease (1999) (113)
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study (2004) (112)
Thalidomide treatment of resistant or relapsed multiple myeloma patients. (2001) (94)
2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland (1999) (79)
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. (2016) (71)
Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. (2006) (67)
The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant (2007) (60)
Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL (2010) (57)
Thymosin increases production of T-cell growth factor by normal human peripheral blood lymphocytes. (1984) (54)
A multicenter, open, non‐comparative, phase II study of the combination of cladribine (2‐chlorodeoxyadenosine), cytarabine, and G‐CSF as induction therapy in refractory acute myeloid leukemia – a report of the Polish Adult Leukemia Group (PALG) (2003) (54)
High-resolution human leukocyte antigen allele and haplotype frequencies of the Polish population based on 20,653 stem cell donors. (2011) (52)
The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation. (2005) (52)
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. (2013) (48)
A tobamovirus of a green alga. (1975) (44)
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. (2004) (43)
Hospital outbreak of vancomycin-resistant enterococci caused by a single clone of Enterococcus raffinosus and several clones of Enterococcus faecium. (2007) (41)
Selection of a Teicoplanin-Resistant Enterococcus faecium Mutant during an Outbreak Caused by Vancomycin-Resistant Enterococci with the VanB Phenotype (2001) (40)
2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger (1999) (39)
Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients (2016) (38)
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia (2001) (37)
Further studies on Chara corallina virus. (1976) (36)
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). (2010) (34)
Laparoscopic removal of retroperitoneal accessory spleen in patient with relapsing idiopathic thrombocytopenic purpura 30 years after classical splenectomy (2002) (33)
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. (2016) (33)
Plasma fatty acid profile in multiple myeloma patients. (2015) (31)
The effect of beta-carotene and its derivatives on cytotoxicity, differentiation, proliferative potential and apoptosis on the three human acute leukemia cell lines: U-937, HL-60 and TF-1. (2005) (30)
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. (2009) (30)
G-CSF Administered in Time-sequenced Setting During Remission Induction and Consolidation Therapy of Adult Acute Lymphoblastic Leukemia has Beneficial Influence on Early Recovery and Possibly Improves Long-term Outcome: A Randomized Multicenter Study (2002) (29)
Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease – a histological study (2003) (29)
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients (2016) (28)
ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. (2005) (27)
In vitro effects of thymosin and lithium on lymphoproliferative responses of normal donors and HIV seropositive male homosexuals with AIDS-related complex. (1987) (27)
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG) (2006) (26)
Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience (2004) (26)
Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. (2018) (25)
Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia (2009) (24)
Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR–ABL-positive acute lymphoblastic leukemia—retrospective analysis of Polish Adult Leukemia Group (PALG) (2006) (23)
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). (2005) (22)
Mechanism of action of thymosin. II. Effects of aspirin and thymosin on enhancement of IL-2 production. (1985) (22)
High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group (2002) (21)
ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. (2003) (20)
Efficacy and Safety of Fludarabine and Cyclophosphamide Combined Therapy in Patients with Refractory/Recurrent B-Cell Chronic Lymphocytic Leukaemia (B-CLL)—Polish Multicentre Study (2004) (20)
Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). (2006) (19)
HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma (2014) (19)
The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group. (2010) (19)
Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network and the PLRG. (2006) (19)
2‐Chlorodeoxyadenosine (cladribine)‐related eosinophilia in patients with lymphoproliferative diseases (1997) (18)
Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study. (2009) (18)
Importance of parenteral nutrition in patients undergoing hemopoietic stem cell transplantation procedures in the autologous system. (2005) (17)
The Gain-of-Function JAK2 V617F Mutation Shifts the Phenotype of Essential Thrombocythemia and Chronic Idiopathic Myelofibrosis to More “Erythremic” and Less “Thrombocythemic”: A Molecular, Histologic, and Clinical Study (2007) (17)
Detection of specific lytic and latent transcripts can help to predict the status of Epstein-Barr virus infection in transplant recipients with high virus load. (2008) (16)
Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen (2018) (16)
The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. (1997) (16)
90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment. (2006) (16)
[Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis]. (2011) (15)
The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment (2015) (15)
Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin® SDH in previously treated patients with severe haemophilia A (2004) (15)
The Microarray Expression Analysis Identifies BAX as a Mediator of β-Carotene Effects on Apoptosis (2005) (15)
An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma (2004) (15)
Percutaneous Vertebroplasty for Pathological Vertebral Compression Fractures Secondary to Multiple Myeloma--Medium-Term and Long-Term Assessment of Pain Relief and Quality of Life. (2015) (14)
Clinical efficacy, safety and pharmacokinetic properties of the plasma‐derived factor IX concentrate Haemonine® in previously treated patients with severe haemophilia B (2012) (14)
Alemtuzumab (CAMPATH®, MABCAMPATH®) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL). (2006) (13)
Coronary artery disease and apolipoprotein A‐I/C‐III gene polymorphism: a study of Saudi Arabians (1991) (13)
The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil. (2005) (13)
Lymphotropic herpesvirus DNA detection in patients with active CMV infection – a possible role in the course of CMV infection after hematopoietic stem cell transplantation (2011) (12)
Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series. (2016) (12)
Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas. (2013) (11)
Thymus transplantation in leukaemia and malignant lymphogranulomatosis. (1973) (11)
The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; The results of multicenter, prospective Polish adult leukemia group study (2011) (11)
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome—Polish Adult Leukemia Group (PALG) pilot study (2008) (11)
Fibrinogen Krakow: A novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325Ile) affecting fibrin clot structure and function (2009) (10)
Biological Properties and Clinical Use of Calf Thymus Extract TFX-Polfa (1984) (10)
The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients (2019) (10)
Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study. (2004) (9)
Severe bleeding and miscarriages in a hypofibrinogenemic woman heterozygous for the gamma Ala82Gly mutation. (2009) (9)
[Methods for freezing, thawing and viability estimation of hemopoietic stem cells]. (1999) (9)
Bleeding tendency and prolonged wound healing in a patient with A alphaArg16His dysfibrinogenemia: fibrinogen Krakow IV. (2012) (9)
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma (2015) (9)
Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: Analysis of prognostic factors and comparison with a single procedure (2007) (8)
RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (2015) (8)
High prevalence of non-Hodgkin's lymphomas in Polish population--1106 new cases diagnosed according to WHO classification in only one district. (2006) (8)
Mixed infection with two tobamoviruses: the formation of particles containing the coat protein messenger RNAs of either virus. (1976) (8)
Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG ‐ CLL4 (ML21283) trial (2018) (8)
Mild chronic graft‐versus‐host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study (2016) (8)
Apolipoprotein A‐l/C‐lll gene cluster polymorphism in Saudi Arabians, Filipinos and Caucasians (1990) (8)
Comparison of the effects of thymosin and other thymic factors on modulation of interleukin-2 production. (1985) (8)
Transcoronary stem cell delivery using physiological endothelium-targeting perfusion technique: the rationale and a pilot study involving a comparison with conventional over-the-wire balloon coronary occlusions in patients after recent myocardial infarction. (2006) (8)
Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study). (2016) (8)
Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results. (2004) (8)
The effect of calf thymus extract (TFX) on human and mouse hemopoiesis. (1981) (7)
Detection of Fiji disease virus in infected sugarcane by nucleic acid hybridization. (1986) (7)
Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up (2019) (7)
New drugs in multiple myeloma – role of carfilzomib and pomalidomide (2014) (7)
Pure red cell aplasia in patients with chronic lymphocytic leukaemia treated with cladribine. (2001) (7)
Incidence of Genomic Aberrations and Associated Efficacy from a Phase III Study Comparing Alemtuzumab (CAMPATH®, MABCAMPATH®) vs Chlorambucil as First Line Therapy for B-Cell Chronic Lymphocytic Leukemia (BCLL). (2006) (6)
A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors (2008) (6)
90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation in Mantle Cell Lymphoma (MCL) Patients, Not Illegible for Intensive Therapy Protocols. (2007) (6)
Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report (2016) (6)
Consolidation of Chemotherapy Response in Mantle Cell Lymphoma (MCL) Patients with 90Y-Ibritumomab Tiuxetan (90Y-Zevalin) Radioimmunotherapy (RIT). (2005) (6)
Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers (2015) (6)
The role of the thymus and thymic humoral factors in immunotherapy of aplastic and proliferative diseases of the hemopoietic system. (1976) (6)
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE-1-RISK MYELOFIBROSIS (MF) FROM AN OPEN-LABEL, MULTICENTER, SINGLE-ARM EXPANDED-ACCESS STUDY (2015) (6)
Therapeutic application of calf thymus extract (TFX) (1989) (6)
Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo‐HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: A retrospective, multicenter Polish Adult Leukemia Group study (2015) (6)
Survival benefit of post induction consolidation therapy in MCL (mantle cell lymphoma): A Polish Lymphoma Research Group (PLRG) retrospective multicenter analysis. (2008) (5)
Coronary Artery Disease, HDL Cholesterol, and Insulin‐gene Flanking Sequences (1989) (5)
In vitro translation of polyribosome-associated RNAs from tobamovirus-infected plants. (1976) (5)
Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia. (2004) (5)
Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients. (2005) (5)
Human recombinant interferon-alpha-2 in the treatment of patients with hairy cell leukemia. (1988) (5)
[The role of magnesium in the pathogenesis and therapy of bronchial asthma]. (1997) (5)
[Hypopituitarism and hematological abnormalities mimicking myelodysplastic syndrome. Report of four cases]. (2003) (5)
[The importance of imaging techniques in the modern treatment of multiple myeloma]. (2014) (5)
[Effect of lithium on the immune system]. (1985) (5)
[Beta-carotene regulates the expression of proapoptotic BAX and CAPN2 in HL-60, U-937 and TF-1 - human acute myeloid leukemia cell lines; microarray, RQ-PCR and Western Blot analysis]. (2011) (5)
[Herpesviruses mixed infections in allogeneic steam cell recipients (allo-HSCT)]. (2008) (5)
A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease. (2012) (5)
The effect of myasthenic thymus fragments transplantation on the immune state of patients with proliferative and aplastic diseases of the haematopoetic system. (1975) (4)
Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia (2014) (4)
[Hepatocyte growth factor: from diagnosis to clinical application]. (2003) (4)
[The role of endothelial progenitor cells for neovascularization]. (2003) (4)
New forms of radionuclide therapy with (90)Y in oncology. (2008) (4)
[Thalidomide induced peripheral neuropathy in multiple myeloma patients]. (2015) (4)
[Daratumumab--breakthrough drug in multiple myeloma therapy]. (2014) (4)
Elongation index of erythrocytes, study of activity of chosen erythrocyte enzymes, and the levels of glutathione, malonyldialdehyde in polycythemia vera (PV). (2011) (4)
CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis. (2015) (4)
Particles produced during a mixed infection by two tobamoviruses contain coat proteins of both viruses. (1977) (4)
A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results (2018) (4)
[Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net]. (2010) (4)
Is it possible to identify siblings by studying bone marrow under a microscope? Two unusual cases of Gaucher disease. (2002) (4)
Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). (2004) (4)
Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study (2010) (4)
Endothelial progenitor cells (EPCs) in therapy (2003) (3)
A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis (2013) (3)
[Veno-occlusive disease--an important complication in hematopoietic cells transplantation]. (2001) (3)
Prognostic Factors in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors- Single Center Experience. (2009) (3)
Effect of the calf thymus extract on immunologic reactivity in patients with hypogammaglobulinaemia. (1975) (3)
[Evaluation of hematopoietic chimerism after allogeneic bone marrow transplantation by modern molecular techniques (STR-PCR and RQ-PCR)--single center]. (2010) (3)
Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine‐based regiments or chlorambucil – follow‐up of PALG‐CLL randomized trials (2013) (3)
Corrosion of concrete and its prevention (1962) (3)
Translation in vitro of artificially produced fragments of a tobamovirus genome. (1976) (3)
Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3). (2008) (3)
Novel translocation (5;18)(q31;q23) in biphenotypic acute leukemia. (2001) (3)
Effect of thymic hormones on interleukin 2 synthesis by lymphocytes from HIV-positive pre-AIDS subjects. (1988) (3)
Overall Survival (OS) Benefit of Rituximab Based Immunochemotherapy Followed by Post-Induction Treatment in Mantle Cell Lymphoma (MCL): a Retrospective Analysis of 279 Patients Treated by Polish Lymphoma Research Group (PLRG) Centers. (2009) (3)
SIROLIMUS EFFECTS IN BIOPSY PROVEN CHRONIC INTERSTITIAL FIBROSIS / TUBULAR ATROPHY IN PEDIATRIC RENAL TRANSPLANTATION: 24 MONTH DATA.: 1637 (2010) (3)
Complex cytogenetics in a case of probably work related MDS/AML. (2004) (3)
The Effect of Magnesium on Immune Response and Carcinogenesis (1994) (3)
Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). (2006) (3)
Randomized Comparison of Cladribine Plus Cyclophsophamide with Fludarabine Plus Cyclophosphamide in Progressive Chronic Lymphocytic Leukemia: An Updated Report of Prospective PALG-CLL3 Study. (2006) (3)
MRI-based evidence for myocardial involvement in women with hypereosinophilic syndrome. (2015) (3)
[Depressive disorders in leukemia]. (2003) (3)
Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study (2009) (2)
[Concomitant myeloid sarcoma and plasma cell myeloma--case report of a hitherto undescribed association of two neoplasms]. (2007) (2)
Digestive Complaints in Patients with Hematologic Malignancies Undergoing Bone Marrow Transplantation (2011) (2)
[Mucositis--a major non-hematologic complication of high-dose chemotherapy and radiotherapy--pathogenesis, prevention and treatment]. (2003) (2)
Morphometric classification of hairy cell leukemia in bone marrow trephine biopsy. (2003) (2)
Fatal post-transplant lymphoproliferative disorder following allogeneic bone marrow transplantation for aplastic anemia. (2002) (2)
Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study, (2011) (2)
Bone marrow suppression with plasma cell leukemia‑like reaction complicated by macrophage activation syndrome after metamizole overuse. (2013) (2)
[Effect of selenium on the growth of carcinogenic fungi and the cytotoxic action of aflatoxin B-1 in cell of lymphocytes and on the embryonal development of Xenopus laevis]. (1975) (2)
[Angiogenesis in different clinical phases of chronic myeloid leukemia]. (2009) (2)
[Agranulocytosis in patients with rheumatoid arthritis treated with levamisole--mechanism and prevention]. (1982) (2)
Addition of Cladribine to the Standard AML Treatment Improves Long-Term Outcome in High Tumor Burden and Older Than 40 Years Acute Myeloid Leukemia Patients. Five-Year Follow-Up of the Polish Adult Leukemia Group (PALG 1999 DAC vs. DA Study). (2004) (2)
Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group's (PLRG) experience. (2007) (2)
[Immunologic aspects of acute and chronic hepatitis -- perspectives of immunotherapy (author's transl)]. (1979) (2)
CORRESPONDENCE: Pure red cell aplasia in patients with chronic lymphocytic leukaemia treated with cladribine (2001) (2)
Use of radioimmunotherapy for consolidation for chemosensitive mantle cell lymphoma (MCL): Summary of International Radioimmunotherapy Registry data. (2010) (2)
Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients (2015) (2)
[Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide]. (2003) (2)
[Infections with Van B phenotype Enterococcus faecium and E. faecalis in patients with immune deficiency during the course of hematologic neoplasms]. (2003) (2)
[Non Hodgkin lymphoma during pregnancy]. (2005) (2)
Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL) (2007) (2)
Impaired Clonogenic Capacity Contributes to Bone Marrow Hypoplasia and Late Hematological Recovery after Zevalin in the Low-Grade NHL Patients. (2004) (2)
[The effect of magnesium on blood coagulation--state of the art literature review from 1959 to 1995]. (1997) (2)
[The frequency of cytomegalovirus infection (CMV) in patients immunocompromised patients with malignant and nonmalignant blood disorders]. (1996) (2)
[Harvesting bone marrow from the posterior superior iliac crest for transplantation]. (1999) (2)
[Post transplant lymphoproliferative disorder (PTLD)--10 years follow-up]. (2011) (2)
[Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease]. (2014) (2)
Early PET assessment and therapy de-escalation in patients with advanced Hodgkin’s lymphoma treated with escalated BEACOPP regimen (2008) (2)
[Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas]. (2013) (2)
[The role of the bone marrow microenvironment in the pathogenesis of multiple myeloma]. (2015) (2)
Imatinib Trough Plasma Concentration and Its Correlation with Clinical Response in Chronic Phase and Accelerated Phase of CML (2008) (2)
[All-trans-retinoic acid in differentiation therapy of hemo-cytopathic proliferative diseases. II. Retinoids in clinical practice]. (1995) (1)
Molecular Biology of Chronic Myeloid Leukemia (2012) (1)
Efficacy and Safety of Fludarabine and Cyclophosphamide Combined Therapy in Patients with Refractory/Recurrent B-Cell Chronic Lymphocytic Leukemia (B-CLL) – Polish Multicentre Study (2004) (1)
The use of the Congo red-related dye DBACR to recognize the heavy chain-derived abnormality of myeloma immunoglobulins (2006) (1)
Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma for 2012 (2015) (1)
Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Cladribine (2008) (1)
[Autotransplantation for solid tumors]. (1999) (1)
[Epstein-Barr virus infection in patients after bone marrow and heart transplantation]. (2001) (1)
[Principles of immunoregulation in autoimmune syndromes]. (1983) (1)
[The diagnostic significance of blast immunophenotype assay in patients with acute leukemia]. (1996) (1)
Abstracts Of Contributed Papers — National Plant Pathology Conference, Sydney, May 1974 (1974) (1)
[Hematological toxicity of radioimmunotherpy with 90Y Ibritumomab]. (2012) (1)
High incidence of cardiovascular mortality caused by acute and early chronic progressive doxorubicin toxicity: Retrospective analysis of 606 patients. (2011) (1)
[Necessary diagnostic requirements and therapeutic recommendations in multiple myeloma]. (2013) (1)
Incidence and transfer of R-plasmids at a hospital in Saudi Arabia. (1987) (1)
High Incidence of tMDS in Elderly Lymphoma Patients Subjected to Radioimmunotherapy (2012) (1)
Improved Survival in Acute Myeloid Leukaemia Patients Aged over 40 Given Cladribine in Combination with Standard Remission Induction (DA 3+7) and Consolidation Treatment (HD AraC). Seven Year Follow-Up of Prospective, Cooperative PALG Study. (2006) (1)
Scalp skin primary cutaneous follicle center lymphoma – Case report (2016) (1)
[Thomson's colchicine test in differential diagnosis of lymphocytic leukemia and non-Hodgkin lymphoma]. (1979) (1)
Consolidation with Radioimmunotherapy May Prolong Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for Stem Cell Transplantation, An Analysis of the International RIT-Network. (2009) (1)
Proteasome Inhibition as a Novel Therapeutic Target in Neoplasmatic Diseases (2006) (1)
Detection of beet western yellows virus by nucleic acid hybridization (1987) (1)
The Significance of Palifermin (Kepivance) in Reduction of Oral Mucositis (OM) Incidence and Acute Graft Versus Host Disease (aGvHD) in Patients with Hematological Diseases Undergoing HSCT. (2006) (1)
[H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience]. (2011) (1)
On the nature of the difference in the densities of the particles of two tobamoviruses. (1976) (1)
Some properties of the virions of galinsoga mosaic virus (1981) (1)
Efficacy and safety of stem cell mobilization with cyclophosphamide plus etoposide versus cyclophosphamide alone. (2015) (1)
[Implementation of direct sequencing as a method of ABL gene mutations analysis in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor]. (2010) (1)
Status of Minimal Residual Disease Determines Outcome of Autologous HSCT in Adults with High-Risk Acute Lymphoblastic Leukemia. (2009) (1)
[Clinical trial of the treatment of dermatomyositis with TFX Polfa]. (1985) (1)
[Escalated BEACOPP as an alternative in high risk Hodgkin lymphoma]. (2012) (1)
[Acquired immunodeficiency syndrome (AIDS) in the African environment]. (1986) (1)
Neopterin and other inflammatory markers in the early period following allogeneic bone marrow transplantation: series of 3 cases. (2009) (1)
Minimal Residual Disease Status Is the Most Important Preditive Factor in Adults with Acute Lymphoblastic Leukemia. Prospective, Multicenter PALG 4-2002 MRD Study. (2007) (1)
[Severe depression with psychotic symptoms, diagnosed in the final stage of treatment of acute bi-phenotype leukemia]. (2002) (1)
[ABL domain kinase point mutations as a cause of resistance to therapy of patients with chronic myeloid leukemia with tyrosine kinase inhibitors. Single center experience]. (2011) (1)
Efficacy, safety and pharmacokinetic results of a phase II/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Willebrand Factor/factor VIII concentrate (Voncento ®) in subjects with hemophilia A (the SWIFT-HA study) (2015) (1)
Quality of Life in Relapsed/Refractory Mantle Cell Lymphoma Patients Treated with Lenalidomide Vs Investigator'S Choice: Mcl-002 (Sprint) Trial (2015) (1)
[Hemorrhagic cystitis related to the high-dose conditioning therapy in a bone marrow recipient]. (2001) (1)
Severe bleeding diathesis associated with moderate thrombocytopenia – diagnostic workup of seven family members with type 2B von Willebrand’s disease (2010) (1)
New drugs in the therapy of multiple myeloma (2007) (1)
[Cutaneous involvement in multiple myeloma--case report and literature review]. (2015) (1)
Prophylaxis of central nervous system (CNS) relapse in high-risk lymphoma patients with liposomal cytarabine. (2011) (1)
[Various aspects of immunopathogenesis of multiple sclerosis and therapeutic possibilities]. (1981) (1)
Primary cardioprotection in lymphoma patients with high risk of cardiovascular disease, treated with (R) CHOP regimen: A single center retrospective analysis. (2015) (1)
[Traumatic epidural hematoma in a patient with von Willebrand's disease]. (2003) (1)
211: The significance of palifermin (Kepivance®) in reduction of oral mucositis (OM) incidence and acute graft versus host disease in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT) (2007) (1)
BK VIRUS HIGH LEVEL REPLICATION IN VITRO REDUCED BY CYCLOSPORINE A, PROXIMAL TUBULE CELL TYPE AND CULTURE ENVIRONMENT (POLARITY) BUT NOT BY TACROLIMUS: 3070 (2010) (1)
[Apoptosis (programmed cell death) in the immune system and hemopoiesis]. (1994) (0)
[Tuberculosis in the course of leukemia]. (1975) (0)
[Prevention of leukemia of the central nervous system in patients with lymphoblastic leukemia]. (1982) (0)
Idarubicin, Cytarabine, Etoposide Versus Risk-Adjusted Daunorubicin Plus Cytosine Arabinoside for Induction Treatment of Acute Myeloid Leukemia: A Randomized Multicenter Trial (1997) (0)
[Preleukemia and "smoldering" leukemia as a clinical and research problem]. (1982) (0)
Daratumumab - przełomowy lek w terapii szpiczaka plazmocytowego Daratumumab - breakthrough drug in multiple myeloma (2014) (0)
Author ' s response to reviews Title : Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma (2014) (0)
Cytoprotective Effect of Palifermin on Gastrointestinal Mucous Membrane Enabled Non-Myeloablative Chemotherapy Administration in ALL Patient with High Risk of Gastrointestinal Toxicity. (2007) (0)
Significance of BAALC, MN1, ERG, CEBPa Gene Expression as New Prognostic Factors, in the Context of Other Molecular Markers in Intermediate Risk AML Group According to Cytogenetics, Including Patients Younger Than 60 Years (2008) (0)
leukemia after failure of first-line imatinib: a randomized phase 2 trial Dasatinib or high-dose imatinib for chronic-phase chronic myeloid (2008) (0)
Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms. (2007) (0)
[Immunopathology and clinical aspects of acquired immunodeficiency syndrome (AIDS)]. (1986) (0)
[Rationale and methods for high dose chemotherapy in oncology]. (1999) (0)
[Decaris in the treatment of patients with recurrent aphthae]. (1984) (0)
[Granulocytic sarcoma with late transformation into acute myeloblastic leukemia--case report]. (2006) (0)
[Methods of mobilizing hematopoietic cells, their collection using cell separation, purging--processing of pathologic cells and enrichment with CD 34+ cells--negative and positive selection]. (1999) (0)
Myeloid sarcoma – a case report (2009) (0)
[Characteristics of the hemopoietic stem cell and its biological marker--the CD34 molecule]. (1999) (0)
C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma. (2005) (0)
Favorable outcome of patients with normal karyotype acute myeloid leukemia harboring FLT3-ITD and treated with cladribine added to daunorubicin and cytarabine induction (2015) (0)
[Long-term survival results according to cytogenetic risk in patients with acute myeloid leukemia--singl center experience]. (2011) (0)
[Therapeutic value of levamisole in rheumatoid arthritis in the light of clinical and laboratory studies]. (1983) (0)
The effect of calf thymus extract on surface structure and lysosomal apparatus in lymphocytes of patients with chronic lymphatic leukemia. (1977) (0)
[Use of immunoglobulin preparations in hematology]. (1987) (0)
[Telomeres and telomerase in leukemias]. (1999) (0)
Combined Schedule of Fludarabine and Alemtuzumab Followed by Maintenance with Low-Dose Alemtuzumab Is Effective for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia. (2005) (0)
[Primary adrenal lymphoma in incidentally discovered adrenal tumour]. (2006) (0)
Extranodal masses compressing spinal cord in Hodgkin's disease and follicular lymphoma (2004) (0)
Skin Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 53 Patients (2015) (0)
Town planning in industrial districts : engineering and economics (1968) (0)
[Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders]. (1994) (0)
Immunoregulatory actions of calf thymus extract (TFX®) in vitro in relation to its effect on expression of mitogen activated protein kinases. (2023) (0)
Diabetes Mellitus Compromises Survival of Young Non Hodgkin Lmphoma Patients Treated with (R) CHOP Chemotherapy - a Retrospective Multicenter Analysis by Polish Lymphoma Study Group (2012) (0)
[Possibility of using interferon in the treatment of multiple myeloma]. (1988) (0)
[Granulocytopoiesis growth factors. II. Clinical applications]. (1990) (0)
Evaluation of Humoral Response to Trivalent Influenza Vaccination in Patients with Non-Hodgkin Lymphoma Previously Treated or Untreated with Chemotherapy. (2004) (0)
[Therapeutic prospects of interferon in patients with chronic myelocytic leukemia]. (1988) (0)
Prospective, Randomized, Multicenter Phase III, Polish Adult Leukemia Group (PALG) Study Comparing DAF (DNR+AraC+Fludarabine), DAC (DNR+AraC+Cladribine), and Standard DA Regimen in Induction of Untreated Acute Myeloid Leukemia Patients - First Report. (2005) (0)
[Selenium, aflatoxins and lymphocyte reactivity (author's transl)]. (1974) (0)
[Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification]. (1999) (0)
[High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience]. (2011) (0)
[Supportive therapy in patients with autologous hemopoietic stem cell transplantation]. (1999) (0)
Increased Expression of Pro-Angiogenic and Decreased Expression of Osteogenic Genes by Multipotential Stromal Cells after Stimulation with Myeloma-Derived Microvesicles. (2007) (0)
[Analysis of epidemiologic-sociocultural and economic course during the AIDS epidemic in the Netherlands and the scenario to the year 2000]. (1992) (0)
[Immunomodulating treatment of patients with HIV infection]. (1989) (0)
[Report of the XII-th International Meeting of the Hematologic Society (European and African Division)]. (1993) (0)
Good but Variable Humoral Response to Trivalent Influenza Vaccination in Patients with Non-Hodgkin’s Lymphoma - Two Seasons Experience. (2005) (0)
High-Dose Therapy Followed by Autologous HSCT in Patients with Multiple Myeloma. Results of a Retrospective Multicenter Analysis Conducted by The Polish Myeloma Group. (2007) (0)
[The role of autologous hematopoietic cell transplantation in adult acute myelogenous leukemia]. (1999) (0)
Manageable and Transient Hematologic Toxicity Associated with 90 Y-Ibritumomab Tiuxetan ( 90 Y-Zevalin) Consolidation of FCM Chemotherapy in Mantle Cell Lymphoma (MCL) Patients. (2005) (0)
The average relative dose intensity of R-CHOP as an independent prognostic factor determining overall survival in diffuse large B cell lymphoma patients. (2018) (0)
[Proteins of the human body--clinical and diagnostic aspects. Hemorrhagic diathesis of plasmatic origin]. (1978) (0)
randomized trial of the Polish Adult Leukemia Group (PALG CLL2) chronic lymphocytic leukemia: report of a prospective, multicenter, cyclophosphamide plus mitoxantrone in the treatment of progressive Cladribine alone and in combination with cyclophosphamide or (2013) (0)
[Management of multiple myeloma-related bone disease]. (2013) (0)
Case Re ports (2005) (0)
Monoclonal Gammopathies Thalidomide treatment of resistant or relapsed multiple myeloma patients (2001) (0)
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies (2023) (0)
[Non Hodgkin's lymphoma--treatment of choice and the role of high dose chemotherapy]. (1999) (0)
[Waldenström's macroglobulinemia--the experts opinion about new therapeutic possibilities and response criteria]. (2004) (0)
[Correlation of serum lactate dehydrogenase activity with bone marrow proliferation in patients with acute myeloblastic leukemia]. (1988) (0)
The choice of first-line therapy in advanced Hodgkin lymphoma: Retrospective comparison of ABVD and escalated BEACOPP regimen (2007) (0)
FCGAMMA RECEPTOR IIIA POLYMORPHISM AND GENE EXPRESSION PROFILE AS POSSIBLE NEW PROGNOSTICAL FACTORS OF DIFFUSE LARGE B-CELL LYMPHOMA (2011) (0)
Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT (2008) (0)
[Nonmyeloablative allogeneic hematopoietic stem cell transplantation: minitransplantation]. (1999) (0)
68 Diagnostic and prognostic significance of elevated percent of fetal hemoglobin containing erythrocytes in patients with myelodysplastic syndromes (1997) (0)
[Autologous hemopoietic stem cell transplantation in treatment of chronic myelogenous leukemia]. (1999) (0)
The Effect of ATRA (Roche) on Clinical and Laboratory Parameters in 36 APL Patients — Polish Multicenter Retrospective Analysis (1998) (0)
Daunorubicin, Cytarabine and Fludarabine (DAF) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Phase II Study by the Polish Adult Leukemia Group (PALG). (2004) (0)
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report (2014) (0)
[The role of antithrombin III in disorders of blood coagulation]. (1988) (0)
[Diagnostics, classification and high dose chemotherapy in non Hodgkin's and Hodgkin's lymphoma]. (1999) (0)
WT1 – a New Marker of Leukaemic Cells (2006) (0)
Boundary Element Analyses of Surface Movement Associated with Faulted Structures (1988) (0)
The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies. (2004) (0)
Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome (2011) (0)
[Effect of magnesium on the development of arteriosclerosis and the status of the cardiovascular system]. (1989) (0)
Idiopathic myelofibrosis with fatty bone marrow: an issue of sampling? A propos an unusual case. (2003) (0)
Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results (2012) (0)
[Myelodysplastic syndromes--diagnostic and therapeutic problems]. (1988) (0)
[Fungal infection in patients with granulocytopenia. Pathogenetic, diagnostic and therapeutic aspects]. (1994) (0)
Myelo-and immunotropic properties of thymic hormones – clinical use in hematology and oncology (2010) (0)
[Main anti-rheumatoidal drugs--the place of levamisole among them]. (1983) (0)
[Granulocytopoietic growth factors. Biological properties]. (1990) (0)
Subject Index, Vol. 7, 1976 (1976) (0)
[Immunotherapy in neoplasms. Part II--methods (author's transl)]. (1975) (0)
Insulin gene flanking sequences in Saudi Arabians and Philipinos (1990) (0)
[Effect of immunomodulators on the production of interleukin 2]. (1985) (0)
A Tobamo virus of Chara corallina. (1974) (0)
Comparison of Myeloma Cells Killing Efficiency by Geldanamycin and Its Analogs. (2006) (0)
Studies on tobamoviruses (1976) (0)
[Autologous transplantation in acute lymphoblastic leukemia in adults]. (1999) (0)
[Aplastic anemia--contemporary procedures and therapeutic perspectives]. (1999) (0)
Contents, Vol. 7, 1976 (1976) (0)
Selenium effect on the growth of carcinogenic fungi and cytotoxic action of aflatoxin B1 on lymphocyte culture and on embryonal development of Xenopus laevis. (1975) (0)
[Tumor necrosis factor (TNF)--its biochemical characteristics and biological properties]. (1989) (0)
The Occurrence of Acute Graft-Versus-Host Disease and Infectious Complications in Patients with Acute and Chronic Myeloid Leukemia who Underwent Allogeneic Peripheral Blood Stem Cell Transplantation (2003) (0)
DLBCL 440 FCGAMMA RECEPTOR IIIA POLYMORPHISM AND GENE EXPRESSION PROFILE AS POSSIBLE NEW PROGNOSTICAL FACTORS OF DIFFUSE LARGE B-CELL LYMPHOMA (2011) (0)
Letter: Thymus transplantation in leukaemia and malignant lymphogranulomatosis. (1974) (0)
[Epstein-Barr virus (EBV) infections in patients treated with allogenic hematopoietic cells transplantation (allo-HCT)]. (2006) (0)
POMALIDOMIDE – A new immunomodulatory drug in the treatment of multiple myeloma (2014) (0)
[History of Kraków hematology]. (2000) (0)
Prolonged hematopoietic reconstitution in patients failing previous peripheral blood stem cell collection, transplanted with adequate number of the CD34 cells obtained during bone marrow harvest. (2004) (0)
[Effect of calf thymus extracts on the surface structure and the lysosomal apparatus of lymphocytes in patients with chronic lymphatic leukemia]. (1976) (0)
[High dose chemotherapy procedures supported by hemopoietic stem cell transplantation in treatment of autoimmune diseases]. (2001) (0)
[Induction of hematologic remission in a patient with acute promyelocytic leukemia through the therapeutic use of trans-retinoic acid]. (1994) (0)
[Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. (2015) (0)
[Multiple sclerosis--immunopathogenesis, traditional therapeutic strategy and suggested combined immunotherapy]. (1983) (0)
[Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy]. (1998) (0)
[Human recombinant alfa-2 interferon in the treatment of hairy cell leukemia]. (1988) (0)
Epidemiology of acute leukemia in adults in Poland in 2004-2006 (2007) (0)
[Preliminary results of transplantation of thymus originating from patients with myasthenia gravis to patients with leukemia and those with Hodgkin's disease]. (1973) (0)
[Hodgkin's disease--diagnostic basis and therapy in light of randomized clinical trials]. (1999) (0)
[Health of patients after bone marrow transplantation and coping with stress -- psychological and medical perspective]. (2013) (0)
[An attempt of immunological stimulation of patients with proliferative and applastic diseases of the haematopoietic system by means of calf's thymus extract (TFX) (author's transl)]. (1975) (0)
Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3-internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission; a retrospective study (2015) (0)
[Epidemiology of bone marrow transplantation performed in Europe and North America]. (1999) (0)
[Psychological health’s predictors of patients after bone marrow transplantation (BMT) 40 years of psychological researches of patients with blood cancers]. (2016) (0)
Evans's Syndrome with Positive Lupus Anticoagulant and Antiphospholipid-Protein Antibodies (1997) (0)
[The effect of magnesium on hemostatic system]. (1973) (0)
[Iron deficiency anaemia in population of Polish patients--results of epidemiological screening study]. (2005) (0)
[Immunopathology of hairy cell leukemia, its infectious complications and therapeutic conclusions]. (1986) (0)
High Incidence of Cardiovascular Complications After CHOP-Like Chemotherapy In Lymphoma Patients From Poland – Retrospective Analysis of Polish Lymphoma Research Group (PLRG) (2010) (0)
Polish multicenter retrospective analysis of immunosuppressive treatment results of adult aplastic anemia patients (1998) (0)
Aspergillus endocarditis in a 33-year-old patient with bone marrow aplasia. (2015) (0)
[Thrombopoietic growth factor--thrombopoietin. Molecular and biological properties]. (1996) (0)
Visceral leishmaniasis diagnosed by trephine biopsy. A case report. (1998) (0)
Importance of Parenteral Nutrition in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (2011) (0)
Liposomal Cytarabine (DepoCyte) Is Effective and Well Tolerated In Prophylaxis of Central Nervous System (CNS) Relapse of High Risk Lymphoma Patients (2010) (0)
Early intensification of imatinib treatment based on precise definition of accelerated phase in patients with chronic myeloid leukemia: Population-based analysis. (2010) (0)
Addition of Purine Analogues to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia. (2004) (0)
[Hematologic remission and disappearance of hemolytic anemia in chronic lymphocytic leukemia after therapy with 2-chlorodeoxyadenosine (2-CDA)]. (1993) (0)
[General characteristics, basis and procedures for high dose chemotherapy procedures supported by hemopoietic stem cell transplantation]. (1999) (0)
The Reduction of Leukemic Blasts In Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia: The Results of Multicenter, Prospective Polish Adult Leukemia Group Study. (2007) (0)
[Effect of the calf thymus extract on immunologic reactivity in patients with hypogammaglobulinemia (author's transl)]. (1976) (0)
Extranodal masses compressing spinal cord in Hodgkin's disease and follicular lymphoma. (2004) (0)
[All-trans-retinoic acid in the differential therapy of proliferative hemocytic diseases. I. Properties of biological retinoids]. (1995) (0)
[The effect of calf thymus extract (TFX) on the survival of mice exposed on ionizing radiation (author's transl)]. (1977) (0)
[Biological activity and physico-chemical properties of TFK thymic extract]. (1978) (0)
[Activity of the Cracow Physicians Society concerning documentation and systematic strengthening of the memory of criminal genocides during World War II]. (2013) (0)
[Hematologic disturbances in patients with nonhematologic neoplasms. I. Anemias]. (1995) (0)
[Multiple myeloma--new therapeutic perspectives]. (1999) (0)
Time-Sequenced G-CSF (Lenograstim) for the Treatment of Adult Acute Lymphoblastic Leukemia - Seven Year Follow-Up of the Polish Adult Leukemia Group 4–96 Study. (2004) (0)
[The history of discovery of the meaning of erythrocyte sedimentation rate (ESR) in the human pathology (in the 150th birth anniversary of the Polish phisician and scientist, Edmund Biernacki)]. (2016) (0)
[Evaluation of transplantation material based on immunophenotype and in vitro clonogenic assays of hematopoietic stem and progenitor cells]. (1999) (0)
[In memory of Prof. Julian Aleksandrowicz]. (1989) (0)
Bortezomib – first proteasome inhibitor for the treatment of multiple myeloma (2007) (0)
[Effect of recombinant human erythropoietin on the bone marrow picture in patients with chronic renal failure treated by hemodialysis]. (1992) (0)
Clinical immunology Rare types of acute leukaemia - analysis of immunophenotype of leukaemia cells (2003) (0)
[Proteins of the human body--clinical and diagnostic aspects. Role of proteins in the blood coagulation and fibrinolysis]. (1978) (0)
[Immunotherapy of neoplasms. Part I - Assumptions (author's transl)]. (1975) (0)
prospective, randomized, multicenter trial first-line therapy in chronic lymphocytic leukemia: report of a Cladribine with prednisone versus chlorambucil with prednisone as (2013) (0)
[IgA multiple myeloma with adverse prognostic factors--a case report]. (2009) (0)
Clofarabine As the Element of Conditioning Regimen in Matched Related Allogeneic Transplantation – Single Center Experience (2012) (0)
The use of tyrosine kinase inhibitors in the second line treatment of patients with chronic myeloid leukemia (2010) (0)
[The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs]. (1998) (0)
[Autologous hematopoietic stem cell transplantation for the treatment of aggressive non-Hodgkin's lymphoma. The experience of Polish lymphoma research group]. (2003) (0)
[Hematologic disturbances in patients with nonhematologic neoplasms. II. Thrombosis, bleedings and leukemoid reaction]. (1995) (0)
[Erythro-tropic human parvovirus B19 (HPV)]. (1993) (0)

This paper list is powered by the following services:

Other Resources About Aleksander Skotnicki

What Schools Are Affiliated With Aleksander Skotnicki ?

Aleksander Skotnicki is affiliated with the following schools:

Aleksander Skotnicki 's Academic­Influence.com Rankings